Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Interventional, Multicentre, Open-label, Randomized Study Comparing Rituximab Plus Zanubrutinib to Rituximab Monotherapy in Previously Untreated, Symptomatic Splenic Marginal Zone Lymphoma (RITZ)

NCT05735834 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.

NCT NCT05735834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Interventional, Multicentre, Open-label, Randomized Study Comparing Rituximab Plus Zanubrutinib to Rituximab Monotherapy in Previously Untreated, Symptomatic Splenic Marginal Zone Lymphoma (RITZ)
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 21, 2024
Completion date
May 31, 2029
Enrollment
122 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

splenic marginal zone lymphoma